VolitionRx: Armistice reports 8.72% stake (9,380,425 shares)
VolitionRx (VNRX): Ownership update — Armistice Capital, LLC and Steven Boyd filed Schedule 13G/A (Amendment No. 4) reporting beneficial ownership of 9,380,425 shares of VolitionRx common stock, representing 8.72% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
VolitionRx (VNRX): Ownership update — Armistice Capital, LLC and Steven Boyd filed Schedule 13G/A (Amendment No. 4) reporting beneficial ownership of 9,380,425 shares of VolitionRx common stock, representing 8.72% of the class. The filing reports shared voting and dispositive power over 9,380,425 shares and no sole voting or dispositive power.
The percentage is based on 107,595,421 shares outstanding as of August 7, 2025, as disclosed by the company. Armistice Capital is the investment manager to the direct holder (Armistice Capital Master Fund Ltd.), and Steven Boyd is Armistice Capital’s managing member. The securities are certified as held in the ordinary course of business and not for the purpose of changing or influencing control.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in VNRX did Armistice Capital report?
What voting and dispositive powers were disclosed for VNRX?
Who are the reporting persons in the VNRX Schedule 13G/A?
Was the VNRX stake reported as a control position?
What is the event date for the VNRX ownership report?
AI-generated analysis. How Rhea-AI works. Not financial advice.